Arcturus Therapeutics Shows Progress Amid Transition: Why I Assign A Hold Rating

Group 1 - Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock has experienced a rise of slightly above 20% this month, resulting in double-digit gains [1] - The company previously thrived during the COVID boom due to large upfront payments and government contracts, which drove peak revenues and visibility [1] Group 2 - The current performance of Arcturus Therapeutics indicates a potential recovery or growth phase following the pandemic-related surge [1]